Friday , January 22 2021
Home / Mike Norman Economics / Successful Not-for-Profit Oxford COVID Vaccine Threatens Big Pharma Profit Logic

Successful Not-for-Profit Oxford COVID Vaccine Threatens Big Pharma Profit Logic

Summary:
“The Oxford vaccine is… striking, since the point was to pay researchers, but not to rely on patent monopolies to generate large profits.” – Economist Dean BakerThe world is abuzz today after a team of medical researchers from Oxford University in the United Kingdom announced that advanced trials of their experimental coronavirus vaccine were a roaring success, with the vaccine possibly being rolled out before Christmas. Testing was done on 24,000 volunteers in the U.K, Brazil, and South Africa, with an average effectiveness of over 70%. However, when the vaccine was administered as a half dose, then patients were later given a full one, effectiveness increased to 90%. Encouragingly, there were no serious side effects registered among any of the volunteers, none of whom had to go to the

Topics:
Mike Norman considers the following as important:

This could be interesting, too:

Asad Zaman writes Marilyn & the Goats: A new solution to an old problem

WARREN MOSLER writes Unemployment claims, consumer sentiment, household debt

Barkley Rosser writes Will North Korea Explode After Biden Becomes President?

Editor writes Lessons from the Moonshot for fixing global problems

“The Oxford vaccine is… striking, since the point was to pay researchers, but not to rely on patent monopolies to generate large profits.” – Economist Dean Baker


The world is abuzz today after a team of medical researchers from Oxford University in the United Kingdom announced that advanced trials of their experimental coronavirus vaccine were a roaring success, with the vaccine possibly being rolled out before Christmas. Testing was done on 24,000 volunteers in the U.K, Brazil, and South Africa, with an average effectiveness of over 70%. However, when the vaccine was administered as a half dose, then patients were later given a full one, effectiveness increased to 90%. Encouragingly, there were no serious side effects registered among any of the volunteers, none of whom had to go to the hospital as a result of being immunized. The U.K. government has already ordered 100 million doses.


Mike Norman
Mike Norman is an economist and veteran trader whose career has spanned over 30 years on Wall Street. He is a former member and trader on the CME, NYMEX, COMEX and NYFE and he managed money for one of the largest hedge funds and ran a prop trading desk for Credit Suisse.

Leave a Reply

Your email address will not be published. Required fields are marked *